TWI779287B - 抗發炎胜肽及包含其之成分 - Google Patents

抗發炎胜肽及包含其之成分 Download PDF

Info

Publication number
TWI779287B
TWI779287B TW109115548A TW109115548A TWI779287B TW I779287 B TWI779287 B TW I779287B TW 109115548 A TW109115548 A TW 109115548A TW 109115548 A TW109115548 A TW 109115548A TW I779287 B TWI779287 B TW I779287B
Authority
TW
Taiwan
Prior art keywords
serial number
peptide
disease
inflammatory
sequence
Prior art date
Application number
TW109115548A
Other languages
English (en)
Chinese (zh)
Other versions
TW202033540A (zh
Inventor
金商在
金京姬
李圭庸
高成昊
金範埈
朴賢喜
許成珍
李宇珍
張華仁
河正順
Original Assignee
韓商傑姆維克斯＆凱爾有限公司
金商在
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120079096A external-priority patent/KR20140012385A/ko
Priority claimed from KR1020120089162A external-priority patent/KR20140022698A/ko
Priority claimed from KR1020120089167A external-priority patent/KR20140022699A/ko
Application filed by 韓商傑姆維克斯＆凱爾有限公司, 金商在 filed Critical 韓商傑姆維克斯＆凱爾有限公司
Publication of TW202033540A publication Critical patent/TW202033540A/zh
Application granted granted Critical
Publication of TWI779287B publication Critical patent/TWI779287B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
TW109115548A 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分 TWI779287B (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
KR1020120079096A KR20140012385A (ko) 2012-07-20 2012-07-20 항염증 활성을 갖는 펩티드 및 이를 포함하는 염증질환 치료용 조성물
KR10-2012-0079096 2012-07-20
KR20120089161 2012-08-14
KR1020120089162A KR20140022698A (ko) 2012-08-14 2012-08-14 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR10-2012-0089162 2012-08-14
KR10-2012-0089161 2012-08-14
KR1020120089167A KR20140022699A (ko) 2012-08-14 2012-08-14 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR10-2012-0089167 2012-08-14
KR10-2012-0104207 2012-09-19
KR20120104144 2012-09-19
KR10-2012-0104144 2012-09-19
KR20120104207 2012-09-19

Publications (2)

Publication Number Publication Date
TW202033540A TW202033540A (zh) 2020-09-16
TWI779287B true TWI779287B (zh) 2022-10-01

Family

ID=47882177

Family Applications (6)

Application Number Title Priority Date Filing Date
TW109115548A TWI779287B (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分
TW113100053A TW202417473A (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分
TW106121753A TWI647311B (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分(一)
TW111118818A TWI836435B (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分
TW108101145A TWI700290B (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分(一)
TW102115615A TWI658141B (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分（一）

Family Applications After (5)

Application Number Title Priority Date Filing Date
TW113100053A TW202417473A (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分
TW106121753A TWI647311B (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分(一)
TW111118818A TWI836435B (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分
TW108101145A TWI700290B (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分(一)
TW102115615A TWI658141B (zh) 2012-07-20 2013-05-01 抗發炎胜肽及包含其之成分（一）

Country Status (8)

Country Link
US (6) US20150125438A1 (enExample)
EP (3) EP3896078B1 (enExample)
JP (6) JP6352911B2 (enExample)
KR (2) KR20150031413A (enExample)
CN (3) CN117551631A (enExample)
ES (3) ES2871899T3 (enExample)
TW (6) TWI779287B (enExample)
WO (1) WO2014012683A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320058D0 (en) 1993-09-29 1993-11-17 Gillette Co Savety razors
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
TWI655204B (zh) 2012-09-19 2019-04-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
KR102201429B1 (ko) 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
ES2929362T3 (es) * 2013-03-15 2022-11-28 Promega Corp Activación de la bioluminiscencia mediante complementación estructural
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
US9757473B2 (en) * 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
KR102494803B1 (ko) 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
EP3130345B9 (en) * 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
ES2962532T3 (es) * 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
WO2016042131A1 (en) * 2014-09-18 2016-03-24 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
KR101662438B1 (ko) 2015-04-07 2016-10-04 가톨릭대학교 산학협력단 X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
KR20250073577A (ko) 2015-05-26 2025-05-27 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
WO2017003267A1 (ko) * 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN108350033A (zh) * 2015-08-28 2018-07-31 威斯康星州医药大学股份有限公司 端粒酶易位的肽抑制剂及其治疗用途
WO2017044885A1 (en) * 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
WO2017176087A1 (ko) * 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR101831888B1 (ko) * 2016-04-15 2018-04-16 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
KR101887577B1 (ko) * 2016-10-19 2018-09-10 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
JP7213811B2 (ja) * 2016-12-22 2023-01-27 ウニヴェルシテ・ドゥ・モンペリエ 新規なステープルペプチドおよびその使用
JP6601848B2 (ja) * 2017-08-21 2019-11-06 株式会社大一商会 遊技機
JP6601849B2 (ja) * 2017-08-21 2019-11-06 株式会社大一商会 遊技機
KR102092843B1 (ko) * 2018-08-30 2020-03-24 충남대학교 산학협력단 암 예방 또는 치료용 펩타이드 및 이의 용도
KR102274658B1 (ko) * 2018-11-16 2021-07-09 주식회사 카인사이언스 염증성 피부질환 치료용 펩타이드 및 이의 용도
KR102032945B1 (ko) * 2018-12-03 2019-10-16 순천대학교 산학협력단 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물
KR102146937B1 (ko) * 2018-12-11 2020-08-21 대한민국 왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물
KR102266613B1 (ko) * 2020-09-21 2021-06-18 자안바이오 주식회사 항염증 활성을 갖는 신규한 펩티드 및 이의 용도
EP4288149A1 (en) * 2021-02-08 2023-12-13 Bacoba AG Treatment of skin disorders
KR20230156265A (ko) * 2022-05-03 2023-11-14 한국생명공학연구원 신규 펩타이드 및 이의 항염 및 재생 용도
KR102827929B1 (ko) * 2023-01-26 2025-07-09 ㈜에빅스젠 신규한 뇌 질환 치료제 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100003229A1 (en) * 2008-06-19 2010-01-07 Santos Janine H Nuclear telomerase reverse transcriptase variant
WO2011101173A1 (en) * 2010-02-16 2011-08-25 Oslo University Hospital Hf Polypeptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
NZ289720A (en) * 1994-07-07 1999-03-29 Geron Corp Nucleic acids coding for a telomerase, a ribonucleoprotein enzyme involved in telomere synthesis
EA002274B1 (ru) * 1996-06-25 2002-02-28 Пфайзер Инк. Призводные замещенного индазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
CN1254376A (zh) * 1996-10-01 2000-05-24 杰龙公司 端粒酶逆转录酶
CN1270634A (zh) * 1997-07-01 2000-10-18 卡姆比亚生物系统有限责任公司 脊椎动物端粒酶基因和蛋白质及其用途
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
EP1423140A2 (en) * 2001-07-31 2004-06-02 Karl Petter Söderström Compositions and methods for modulation of immune responses
US20060127894A1 (en) * 2001-08-08 2006-06-15 Incyte Corporation Protein associated with cell growth, differentiation, and death
US8492438B2 (en) * 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
AU2004236708A1 (en) * 2003-05-01 2004-11-18 Musc Foundation For Research Development An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
CN101011571A (zh) * 2006-03-13 2007-08-08 上海交通大学医学院 GADD45 β 蛋白及其抑制剂在类风湿关节炎中的应用
AU2007298494B2 (en) * 2006-09-21 2013-09-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
ATE534661T1 (de) * 2006-10-12 2011-12-15 Angeletti P Ist Richerche Bio Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
AU2008252628A1 (en) 2007-05-18 2008-11-27 Inhibox Ltd. Bicyclosulfonyl acid (BCSA) compounds and their use as therapeutic agents
WO2009025871A1 (en) 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
DK2310044T3 (en) * 2008-06-16 2016-12-12 Mediolanum Farm S P A Antitumor IMMUNOTHERAPY
WO2010032322A1 (ja) 2008-09-22 2010-03-25 日清ファルマ株式会社 抗炎症性ペプチド
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
KR101284772B1 (ko) 2011-05-24 2013-07-17 정종문 항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko) 2011-05-31 2012-12-11 주식회사 바이오포트코리아 아스타잔틴을 포함하는 항염증제
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
WO2014046481A1 (ko) 2012-09-19 2014-03-27 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
TWI655204B (zh) 2012-09-19 2019-04-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
KR102201429B1 (ko) 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
CN105535931A (zh) * 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
US9757473B2 (en) 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
KR20250073577A (ko) 2015-05-26 2025-05-27 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
US20170112941A1 (en) 2015-10-13 2017-04-27 Symic Ip, Llc Ve-cadherin binding bioconjugate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100003229A1 (en) * 2008-06-19 2010-01-07 Santos Janine H Nuclear telomerase reverse transcriptase variant
WO2011101173A1 (en) * 2010-02-16 2011-08-25 Oslo University Hospital Hf Polypeptides

Also Published As

Publication number Publication date
EP3896078C0 (en) 2025-11-19
KR20200085927A (ko) 2020-07-15
KR20150031413A (ko) 2015-03-24
JP6352911B2 (ja) 2018-07-04
TWI836435B (zh) 2024-03-21
KR102302392B1 (ko) 2021-09-16
EP2875042B1 (en) 2018-08-08
EP3896078A1 (en) 2021-10-20
JP2021011502A (ja) 2021-02-04
JP2019151638A (ja) 2019-09-12
US11098294B2 (en) 2021-08-24
CN109777791B (zh) 2023-12-01
ES3055196T3 (en) 2026-02-10
EP3428182A3 (en) 2019-02-27
JP2017158561A (ja) 2017-09-14
US20210388328A1 (en) 2021-12-16
US11905536B2 (en) 2024-02-20
JP7440581B2 (ja) 2024-02-28
JP2024056904A (ja) 2024-04-23
TW201742921A (zh) 2017-12-16
EP3428182A2 (en) 2019-01-16
TW201938579A (zh) 2019-10-01
TWI658141B (zh) 2019-05-01
EP2875042A1 (en) 2015-05-27
JP2022166225A (ja) 2022-11-01
US20200140832A1 (en) 2020-05-07
CN104470947A (zh) 2015-03-25
US20170275603A1 (en) 2017-09-28
EP3428182B1 (en) 2021-04-21
JP2015525768A (ja) 2015-09-07
US20150125438A1 (en) 2015-05-07
TW202033540A (zh) 2020-09-16
ES2693321T3 (es) 2018-12-11
US20200208127A1 (en) 2020-07-02
TW201406957A (zh) 2014-02-16
JP6788062B2 (ja) 2020-11-18
CN117551631A (zh) 2024-02-13
JP7741218B2 (ja) 2025-09-17
JP6514259B2 (ja) 2019-05-15
WO2014012683A1 (en) 2014-01-23
CN109777791A (zh) 2019-05-21
JP7128246B2 (ja) 2022-08-30
TW202237629A (zh) 2022-10-01
EP3896078B1 (en) 2025-11-19
TWI647311B (zh) 2019-01-11
CN104470947B (zh) 2019-03-08
US20240158768A1 (en) 2024-05-16
ES2871899T3 (es) 2021-11-02
TWI700290B (zh) 2020-08-01
TW202417473A (zh) 2024-05-01

Similar Documents

Publication Publication Date Title
US11905536B2 (en) Anti-inflammatory peptides and composition comprising the same
US12171812B2 (en) Anti-inflammatory peptides and composition comprising the same

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent